2025

“Former Louisiana Attorney General Kahn Swick & Foti LLC Reminds Investors of Lead Plaintiff Deadline in KYVERNA THERAPEUTICS Shareholder Alert – Losses Exceeding $100,000”

newsmaker03 mins

New Orleans Securities Law Firm Reminds Investors of Upcoming Deadline Background On January 28, 2025, Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., issued a reminder to investors regarding an upcoming deadline in a securities class action lawsuit against Kyverna Therapeutics, Inc. (“Kyverna” or the…

Read More

“Breaking News: Bitwise Files S1 for Dogecoin ETF with US SEC – What This Means for the Crypto Market”

financenews04 mins

Asset Management Firm Bitwise Files for Dogecoin ETF Introduction Asset management firm Bitwise is making waves in the cryptocurrency world with its latest move to push for a Dogecoin Exchange-Traded Fund (ETF). The firm has recently filed the S-1 registration statement with the United States Securities and Exchange Commission (SEC) for the Bitwise Dogecoin ETF,…

Read More

“Former Louisiana Attorney General’s Firm Reminds Investors of Lead Plaintiff Deadline in SYMBOTIC Class Action Lawsuit: Losses Exceeding $100,000”

newsit04 mins

New Orleans Security Class Action Lawsuit Alert Act Now: Deadline Approaching for Symbotic Inc. Investors January 28, 2025 Kahn Swick & Foti, LLC (“KSF”) along with KSF partner and former Attorney General of Louisiana, Charles C. Foti, Jr., are urging investors to take action. The deadline for filing lead plaintiff applications in a securities class…

Read More

“Trade Tensions and Economic Data Await: AUD/USD Slides on the Global Stage”

marketinsights03 mins

AUD/USD Extends Losing Streak Near 0.6250 Amid Trade War Anxieties The Australian dollar has continued to slide against the US dollar, with the AUD/USD pair hovering near the 0.6250 level. The ongoing trade tensions between the United States and various countries, including Colombia, have intensified market concerns and fueled risk aversion. US President Trump’s recent…

Read More

“89bio Inc. Sets the Stage for Growth: Announces Successful Pricing of $250 Million Public Offering of Common Stock and Pre-Funded Warrants”

newscaster03 mins

89bio, Inc. Announces Pricing of Upsized Public Offering Introduction On January 28, 2025, 89bio, Inc. (“89bio”) made a significant announcement regarding the pricing of its upsized underwritten public offering. The clinical-stage biopharmaceutical company, focused on developing innovative therapies for liver and cardiometabolic diseases, revealed the details of the offering which includes the issuance of common…

Read More